These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 15987690

  • 21. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase.
    Thomas VL, Golemi-Kotra D, Kim C, Vakulenko SB, Mobashery S, Shoichet BK.
    Biochemistry; 2005 Jul 05; 44(26):9330-8. PubMed ID: 15981999
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
    Lin S, Thomas M, Shlaes DM, Rudin SD, Knox JR, Anderson V, Bonomo RA.
    Biochem J; 1998 Jul 15; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
    [Abstract] [Full Text] [Related]

  • 24. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
    Papp-Wallace KM, Taracila M, Hornick JM, Hujer AM, Hujer KM, Distler AM, Endimiani A, Bonomo RA.
    Antimicrob Agents Chemother; 2010 Jul 15; 54(7):2867-77. PubMed ID: 20421396
    [Abstract] [Full Text] [Related]

  • 25. Substitution of Arg-244 by Cys or Ser in SHV-1 and SHV-5 beta-lactamases confers resistance to mechanism-based inhibitors and reduces catalytic efficiency of the enzymes.
    Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS.
    FEMS Microbiol Lett; 1998 Mar 01; 160(1):49-54. PubMed ID: 9495011
    [Abstract] [Full Text] [Related]

  • 26. The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
    Mendonça N, Manageiro V, Robin F, Salgado MJ, Ferreira E, Caniça M, Bonnet R.
    Antimicrob Agents Chemother; 2008 May 01; 52(5):1806-11. PubMed ID: 18316518
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
    Kalp M, Totir MA, Buynak JD, Carey PR.
    J Am Chem Soc; 2009 Feb 18; 131(6):2338-47. PubMed ID: 19161282
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Detection of extended-spectrum β-lactamases producing Enterobacteriaceae using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry based MBT STAR-BL software module with β-lactamase inhibition assay depends on the bacterial strains.
    Ota Y, Furuhashi K, Nagao Y, Nanba T, Yamanaka K, Ishikawa J, Nagura O, Iwaizumi M, Hamada E, Maekawa M.
    J Microbiol Methods; 2019 Dec 18; 167():105734. PubMed ID: 31689450
    [Abstract] [Full Text] [Related]

  • 32. Sensitivity and specificity of various beta-lactam antibiotics and phenotypical methods for detection of TEM, SHV and CTX-M extended-spectrum beta-lactamases.
    Bedenic B, Vranes J, Mihaljevic Lj, Tonkic M, Sviben M, Plecko V, Kalenic S.
    J Chemother; 2007 Apr 18; 19(2):127-39. PubMed ID: 17434820
    [Abstract] [Full Text] [Related]

  • 33. Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.
    Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M, Anderson VE, Fritsche TR, Jones RN, Pagadala SR, van den Akker F, Buynak JD, Bonomo RA.
    J Biol Chem; 2009 Jan 09; 284(2):945-53. PubMed ID: 18955486
    [Abstract] [Full Text] [Related]

  • 34. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC, Ostergaard BE.
    Am J Health Syst Pharm; 1995 Mar 15; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [Abstract] [Full Text] [Related]

  • 35. Homology modeling and virtual screening of inhibitors against TEM- and SHV-type-resistant mutants: A multilayer filtering approach.
    Baig MH, Balaramnavar VM, Wadhwa G, Khan AU.
    Biotechnol Appl Biochem; 2015 Mar 15; 62(5):669-80. PubMed ID: 25779642
    [Abstract] [Full Text] [Related]

  • 36. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA, Rudin SA, Shlaes DM.
    FEMS Microbiol Lett; 1997 Mar 01; 148(1):59-62. PubMed ID: 9066111
    [Abstract] [Full Text] [Related]

  • 37. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
    Sun T, Bethel CR, Bonomo RA, Knox JR.
    Biochemistry; 2004 Nov 09; 43(44):14111-7. PubMed ID: 15518561
    [Abstract] [Full Text] [Related]

  • 38. Amino acid substitutions causing inhibitor resistance in TEM beta-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum beta-lactamases.
    Randegger CC, Hächler H.
    J Antimicrob Chemother; 2001 May 09; 47(5):547-54. PubMed ID: 11328764
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of OXA-1 beta-lactamase by penems.
    Bethel CR, Distler AM, Ruszczycky MW, Carey MP, Carey PR, Hujer AM, Taracila M, Helfand MS, Thomson JM, Kalp M, Anderson VE, Leonard DA, Hujer KM, Abe T, Venkatesan AM, Mansour TS, Bonomo RA.
    Antimicrob Agents Chemother; 2008 Sep 09; 52(9):3135-43. PubMed ID: 18559643
    [Abstract] [Full Text] [Related]

  • 40. Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant.
    Prinarakis EE, Miriagou V, Tzelepi E, Gazouli M, Tzouvelekis LS.
    Antimicrob Agents Chemother; 1997 Apr 09; 41(4):838-40. PubMed ID: 9087500
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.